宜明昂科-B(01541)提交IMM2510 III期臨牀試驗申請

宜明昂科-B(01541)提交IMM2510用於治療耐藥性非小細胞肺癌的III期臨牀試驗申請，股價上漲6.69%，國元國際研報稱其研發管線豐富，有望成爲重磅藥物。

相關股票

相關資訊

港股異動 | 宜明昂科-B大漲8%！已向CDE提交IMM2510的III期臨牀試驗申請

智通财经·2025/10/03

港股異動 | 宜明昂科-B大漲8%！已向CDE提交IMM2510的III期臨牀試驗申請

港股異動 | 宜明昂科-B(01541.HK)再漲超6% 已向CDE提交IMM2510的III期臨牀試驗申請

智通财经·2025/10/03

港股異動 | 宜明昂科-B(01541.HK)再漲超6% 已向CDE提交IMM2510的III期臨牀試驗申請

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/economy/92c4b57cc171fa2e98d252f2e284036e"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://community-service.laohu8.com/v1/financial/theme/news\",params:#themeId:\"92c4b57cc171fa2e98d252f2e284036e\",region:\"SGP\",,,undefined,":{"bottom":false,"list":[{"cardType":"NEWS","cardId":"NEWS.2572572094","cardData":[{"id":"2572572094","pubTimestamp":1759476661,"title":"港股異動 | 宜明昂科-B大漲8%！已向CDE提交IMM2510的III期臨牀試驗申請","summary":"","media":"智通财经","labels":["corporation"],"importantFlag":0,"likeCount":0,"liked":false,"publishNews":true,"publishLive":false,"news_tag":"corporation"}],"position":0},{"cardType":"NEWS","cardId":"NEWS.2572557209","cardData":[{"id":"2572557209","pubTimestamp":1759474903,"title":"港股異動 | 宜明昂科-B(01541.HK)再漲超6% 已向CDE提交IMM2510的III期臨牀試驗申請","summary":"","media":"智通财经","labels":[],"importantFlag":0,"likeCount":0,"liked":false,"publishNews":false,"publishLive":true}],"position":0}],"size":2,"extra":{"requestId":"6cd966ea5acb414fb741b88f7d2f8024"}},"@#url:\"https://community-service.laohu8.com/v1/theme/info\",params:#region:\"SGP\",,method:\"POST\",data:#themeId:\"92c4b57cc171fa2e98d252f2e284036e\",,,undefined,":{"themeId":"92c4b57cc171fa2e98d252f2e284036e","name":"宜明昂科-B(01541)提交IMM2510 III期臨牀試驗申請","description":"宜明昂科-B(01541)提交IMM2510用於治療耐藥性非小細胞肺癌的III期臨牀試驗申請，股價上漲6.69%，國元國際研報稱其研發管線豐富，有望成爲重磅藥物。","image":"https://static.tigerbbs.com/75893bea54132997d986d37d06d63387","type":2,"style":4,"follow":false,"createTime":1759477546110,"userCounts":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/special/finance&rndata={\"themeId\":92c4b57cc171fa2e98d252f2e284036e}&rnconfig={\"headerBarHidden\": true}","subscribe":false,"allowFollow":false,"hasReward":false,"rewardScore":0,"rewardValidDate":0,"rewardEnd":false,"symbols":["01541"],"tweetCounts":0,"categoryId":"2929bb7468f5415f853fd96fb35d7c3b","options":[],"votedOptionId":"","totalUserCount":0,"followStatus":false,"themeName":"宜明昂科-B(01541)提交IMM2510 III期臨牀試驗申請","tweetAmount":0,"imageIsDefault":false}}}